Back to results
US 2025/0375523 A1Published application
Compositions and systems for combinatorial therapies containing fucosylated cells and immune checkpoint inhibitors and methods of production and use thereof
AssigneeTargazyme, Inc.
InventorsReid P. BISSONNETTE, Lynnet KOH
Life of this patent
Estimating the term…
Abstract
Compositions, systems, and kits are disclosed that comprise at least one immune checkpoint inhibitor and at least one immune cell type for adoptive cell therapy, wherein the at least one immune cell type has been fucosylated ex vivo (fuco-ACT). Also disclosed are methods of making and using the compositions, systems, and kits.
Claims21
An adoptive cell therapeutic pharmaceutical composition, comprising:
- at least one isolated immune cell type that has been fucosylated ex vivo;
- at least one immune checkpoint inhibitor;
- and
- at least one pharmaceutically acceptable carrier.
1 more element
A system, comprising:
- a composition comprising at least one immune checkpoint inhibitor (ICI);
- and
- a composition comprising at least one fucosylated immune cell type for adoptive cell therapy (fuco-ACT).
An adoptive cell therapy method, comprising the steps of:
- 1) identifying a cancer patient in need of adoptive cell therapy;
- 2) isolating immune cells from the patient's blood or cancer tumor;
- 3) expanding the immune cells ex vivo;
- 4) contacting the expanded immune cells with a fucosyltransferase and at least one of fucose or GDP-fucose to provide fucosylated immune cells;
- 5) returning the fucosylated immune cells to the patient intravenously;
- and
- 6) administering at least one immune checkpoint inhibitor to the patient simultaneously or wholly or partially sequentially with the fucosylated immune cells.
4 more elements
A method of treating one or more cancers and reducing the occurrence of metastasis in a cancer patient, the method comprising the step of:
- administering to the cancer patient, either simultaneously or wholly or partially sequentially, a combination of at least one ICI and at least one fucosylated immune cell type for adoptive cell therapy (fuco-ACT).
Dependencies are inferred from the claim text.